"We designed Virgil with the input of our own clinicians, and over the last seven years we've continued to refine the platform based on the feedback we regularly seek from the clinicians who are its primary users," said MedAvante CEO Paul Gilbert. "Virgil's clinician-driven development and the resulting user-friendliness are what sets Virgil apart as the leading eCOA solution."
Adds MedAvante President Amy Ellis: "This newest release adds to the array of tools we have to deliver high-quality trial data and strengthens our position as the pioneer in signal detection."
The Virgil platform ensures the speed and accuracy of trial data and reduces administrative burden on trial sites. As easy to use as paper, it is integrated with MedAvante's clinician services, which reduce the risks of bias and measurement variability in clinical trials.
MedAvante is the global clinical data services company dedicated to maximizing signal detection in clinical trials. Founded in 2002, MedAvante pioneered Central Ratings, a groundbreaking clinical trial methodology. This heritage of clinical expertise, coupled with technical innovation and operational skills, enabled MedAvante to develop the electronic source (eSource) platform, Virgil, the first such technology to replace costly and error-prone paper rating scales with real-time digital collection and cloud management of source data. Designed by clinicians for clinicians, Virgil offers built-in clinical guidance to ensure accurate, standardized assessments. MedAvante helps brings better drug therapies to market through smarter, faster clinical trials. Based in Hamilton, NJ with operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit www.medavante.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medavante-unveils-updated-virgil-esource-platform-to-further-streamline-user-experience-enhance-data-quality-300340500.html
SOURCE MedAvante, Inc.